Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Gossamer Bio Inc
GOSS
Healthcare
Biotechnology
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor...
(CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, a and ß, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:GOSS)
New Post
View:
Posts & Comments
Threaded Posts
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 26, 2024 4:47pm
Gossamer Bio Announces Data Presentations at the European Re
News; $GOSS Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024- Additional Phase 2 TORREY Open-Label Extension Data to be Presented in Vienna - Gossamer Bio
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 21, 2024 8:15pm
Presenting on the Emerging Growth Conference 74 Day 2 on Aug
BREAKING NEWS: $GOSS Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register NowMIAMI, Aug. 21, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 25, 2024 10:45am
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
NEWS: $GOSS Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying | BenzingaThe Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates
...more
(0)
•••
Saaaa1
X
View Profile
View Bullboard History
Post by
Saaaa1
on May 06, 2021 8:34pm
$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀
iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver, British Columbia - (Newsfile Corp. - April 20, 2021) - iMining
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product
Do you want to stay ahead of the markets? See how DealRoom can help.
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight